Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
ANG1005 in Leptomeningeal Disease From Breast Cancer
- Conditions
- HER2-negative Breast CancerLeptomeningeal CarcinomatosisLeptomeningeal MetastasesBrain Metastases
- Interventions
- Drug: Physician's Best Choice
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 150
- Registration Number
- NCT03613181
Expanded Access to ANG1005 for Individual Patients
- Conditions
- Breast Cancer With Recurrent Brain MetastasesAnaplastic OligodendrogliomaLeptomeningeal CarcinomatosisAnaplastic Astrocytoma
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Angiochem Inc
- Registration Number
- NCT02755987
- Locations
- 🇺🇸
UC Irvine Health, Orange, California, United States
🇺🇸Univeristy of Texas Health Science Center in San Antonio, San Antonio, Texas, United States
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 72
- Registration Number
- NCT02048059
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸University of California - LAC Medical Center, Los Angeles, California, United States
ANG1005 in Patients With Recurrent High-Grade Glioma
- Conditions
- GliomaGlioblastomaBrain Tumor, Recurrent
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 73
- Registration Number
- NCT01967810
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
- Conditions
- Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 16
- Registration Number
- NCT01497665
- Locations
- 🇺🇸
Univ. of California San Diego, La Jolla, California, United States
🇺🇸Univ. Coloardo at Denver, Aurora, Colorado, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
- Prev
- 1
- 2
- Next